Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis

Nature Medicine

Volumn 14, Issue 12, 2008, Pages 1343-1350

  Chung, Wen Hung ^a,b,c   Hung, Shuen Iu ^b,c   Yang, Jui Yung ^a   Su, Shih Chi ^b   Huang, Shien Ping ^b   Wei, Chun Yu ^b   Chin, See Wen ^c   Chiou, Chien Chun ^a   Chu, Sung Chao ^d   Ho, Hsin Chun ^a   Yang, Chih Hsun ^a   Lu, Chi Fang ^e   Wu, Jer Yuarn ^b   Liao, You Di ^b   Chen, Yuan Tsong ^b,f  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^e Chung Shan Hospital   (Taiwan)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; GRANULYSIN; GRANZYME B; PERFORIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLISTER; CELL DEATH; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MOUSE; NATURAL KILLER CELL; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SKIN DEFECT; STEVENS JOHNSON SYNDROME; TOXIC EPIDERMAL NECROLYSIS;

ANIMALS; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; BIOPSY; BLISTER; EPIDERMIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMANS; KERATINOCYTES; KILLER CELLS, NATURAL; MICE; MICE, NUDE; MOLECULAR WEIGHT; NECROSIS; STEVENS-JOHNSON SYNDROME; T-LYMPHOCYTES, CYTOTOXIC;

EID: 57349198641     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.1884     Document Type: Article

References (28)

1. Gomes, E.R. & Demoly, P. Epidemiology of hypersensitivity drug reactions. Curr. Opin. Allergy Clin. Immunol. 5, 309-316 (2005).
2. Roujeau, J.C. & Stern, R.S. Severe adverse cutaneous reactions to drugs. N. Engl. J. Med. 331, 1272-1285 (1994).
3. Roujeau, J.C. The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. J. Invest. Dermatol. 102, 28S-30S (1994).
4. Paul, C. et al. Apoptosis as a mechanism of keratinocyte death in toxic epidermal necrolysis. Br. J. Dermatol. 134, 710-714 (1996).
5. Roujeau, J.C. Immune mechanisms in drug allergy. Allergol. Int. 55, 27-33 (2006).
6. Nassif, A. et al. Drug specific cytotoxic T cells in the skin lesions of a patient with toxic epidermal necrolysis. J. Invest. Dermatol. 118, 728-733 (2002).
7. Nassif, A. et al. Toxic epidermal necrolysis: effector cells are drug-specific cytotoxic T cells. J. Allergy Clin. Immunol. 114, 1209-1215 (2004).
8. Chung, W.H. et al. Medical genetics: a marker for Stevens-Johnson syndrome. Nature 428, 486 (2004).
9. Hung, S.I. et al. HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. Proc. Natl. Acad. Sci. USA 102, 4134-4139 (2005).
10. Quinn, A.M. et al. Uncovering histologic criteria with prognostic significance in toxic epidermal necrolysis. Arch. Dermatol. 141, 683-687 (2005).
11. Viard, I. et al. Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. Science 282, 490-493 (1998).
12. Pereira, F.A., Mudgil, A.V. & Rosmarin, D.M. Toxic epidermal necrolysis. J. Am. Acad. Dermatol. 56, 181-200 (2007).
13. Abe, R. et al. Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. Am. J. Pathol. 162, 1515-1520 (2003).
14. Stur, K., Karlhofer, F.M. & Stingl, G. Soluble FAS ligand: a discriminating feature between drug-induced skin eruptions and viral exanthemas. J. Invest. Dermatol. 127, 802-807 (2007).
15. Brönnimann, M. & Yawalkar, N. Histopathology of drug-induced exanthems: is there a role in diagnosis of drug allergy? Curr. Opin. Allergy Clin. Immunol. 5, 317-321 (2005).
16. Chave, T.A., Mortimer, N.J., Sladden, M.J., Hall, A.P. & Hutchinson, P.E. Toxic epidermal necrolysis: current evidence, practical management and future directions. Br. J. Dermatol. 153, 241-253 (2005).
17. Gamen, S. et al. Granulysin-induced apoptosis. I. Involvement of at least two distinct pathways. J. Immunol. 161, 1758-1764 (1998).
18. Stenger, S. et al. An antimicrobial activity of cytolytic T cells mediated by granulysin. Science 282, 121-125 (1998).
19. Hanson, D.A., Kaspar, A.A., Poulain, F.R. & Krensky, A.M. Biosynthesis of granulysin, a novel cytolytic molecule. Mol. Immunol. 36, 413-422 (1999).
20. Krensky, A.M. & Clayberger, C. Granulysin: a novel host defense molecule. Am. J. Transplant. 5, 1789-1792 (2005).
21. Anderson, D.H. et al. Granulysin crystal structure and a structure-derived lytic mechanism. J. Mol. Biol. 325, 355-365 (2003).
22. Pardo, J. et al. A role of the mitochondrial apoptosis-inducing factor in granulysin-induced apoptosis. J. Immunol. 167, 1222-1229 (2001).
23. Deng, A. et al. Granulysin, a cytolytic molecule, is also a chemoattractant and proinflammatory activator. J. Immunol. 174, 5243-5248 (2005).
24. Peña, S.V., Hanson, D.A., Carr, B.A., Goralski, T.J. & Krensky, A.M. Processing, subcellular localization, and function of 519 (granulysin), a human late T cell activation molecule with homology to small, lytic, granule proteins. J. Immunol. 158, 2680-2688 (1997).
25. Ogawa, K. et al. Granulysin in human serum as a marker of cell-mediated immunity. Eur. J. Immunol. 33, 1925-1933 (2003).
26. Nagasawa, M. et al. Analysis of serum granulysin in patients with hematopoietic stem-cell transplantation: its usefulness as a marker of graft-versus-host reaction. Am. J. Hematol. 81, 340-348 (2006).
27. Balaji, K.N. et al. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J. Exp. Med. 196, 493-503 (2002).
28. + lymphocytes in the blister fluid of severe acute cutaneous graft-versus-host disease: further similarities with toxic epidermal necrolysis. Dermatology 203, 212-216 (2001).